Controlling CRISPR-Cas9 Gene Editing

New England Journal of Medicine
July 18, 2019 Vol. 381 No. 3


Clinical Implications of Basic Research
Controlling CRISPR-Cas9 Gene Editing
Steven F. Dowdy, Ph.D.
Off-target DNA editing by the CRISPR-Cas9 ribonucleoprotein nuclease in the experimental treatment of genetic disease is a safety concern. A recent study provides proof of principle of an oligonucleotide-based “quencher” that blocks its activity.